Recurrent Mantle Cell Lymphoma Completed Phase 2 Trials for Patupilone (DB03010)

Also known as: Mantle Cell Lymphoma Recurrent

IndicationStatusPhase
DBCOND0028615 (Recurrent Mantle Cell Lymphoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00058019Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaTreatment